Patrick J Heron bought $9.0M of Mirum Pharmaceuticals (MIRM)
Executed Jan 23, disclosed Jan 27, 4 days later.
Over the 21 trading sessions from the disclosed entry session (Jan 27), the stock returned +12.1% (delay-adjusted); from the execution session (Jan 23), +10.0%. Derived: entry at the session's open, exit at the close 20 sessions later.
Patrick J Heron (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in MBX. Across 1 priced purchase filing, the average 21-session return was +10.0% from execution and +12.1% from disclosure (delay-adjusted; derived). The largest single filing was $9.0M of MIRM (131,425 sh × $68.48, as filed), executed Jan 23.
Healthcare · Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitat…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→